SCHEMBL8419134

SCHEMBL8419134

Cc1ccnc(NCc2ccc(F)cc2)c1

nearest known ligand 0.72

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 3/20 0.72
KMT2A Q03164 3/20 0.72
POLB P06746 1/20 0.72
NOS2 P35228 1/20 0.71
KDM4E B2RXH2 2/20 0.58
ALDH1A1 P00352 2/20 0.58
HPGD P15428 2/20 0.58
MAPK14 Q16539 3/20 0.52
MAPK13 O15264 1/20 0.52
MAPK12 P53778 1/20 0.52
MAPK11 Q15759 1/20 0.52
NPC1 O15118 3/20 0.51
RAB9A P51151 2/20 0.51
TP53 P04637 1/20 0.51
SMN1; SMN2 Q16637 1/20 0.51
ITGB3 P05106 1/20 0.47
ITGB1 P05556 1/20 0.47
ITGAV P06756 1/20 0.47
ITGA2B P08514 1/20 0.47
ITGA5 P08648 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10986892 0.84 POLB (1.00) MEN1KMT2APOLBNOS2KDM4E
SCHEMBL15830494 0.83 NOS2 (0.76) MEN1KMT2APOLBNOS2KDM4E
SCHEMBL3175243 0.83 NOS2 (1.00) MEN1KMT2APOLBNOS2KDM4E
SCHEMBL21672225 0.83 KDM4E (0.56) MEN1KMT2APOLBNOS2KDM4E
SCHEMBL8422251 0.81 MEN1 (0.68) MEN1KMT2APOLBNOS2KDM4E
SCHEMBL8229603 0.80 KDM4E (0.54) MEN1KMT2APOLBNOS2KDM4E
SCHEMBL14818976 0.77 KDM4E (0.50) MEN1KMT2APOLBKDM4EALDH1A1
SCHEMBL10086677 0.76 ALDH1A1 (0.67) MEN1KMT2APOLBNOS2KDM4E
SCHEMBL16220824 0.75 NOS2 (0.72) MEN1KMT2APOLBNOS2KDM4E
SCHEMBL5174898 0.75 KMT2A (0.59) MEN1KMT2APOLBNOS2KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070142369-A1 Combination of an H3 antagonist/inverse agonist and an appetite suppressant SCHERING CORPORATION 2007-06-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070142369-A1 Combination of an H3 antagonist/inverse agonist and an appetite suppressant CNR2, GPR119, GLP1R MEN1 991/4885KMT2A 193/4885POLB 4772/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.